Role of intestinal flora in the development of nonalcoholic fatty liver disease in children
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI
Authors
Zhang J, Shi M, Zhao C, Liang G, Li C, Ge X, Pei C, Kong Y, Li D, Yang W, Cao B, Fu L, Yan Y, Wu J, Zhou J, Fang Y, Meng X, Li Y, Wang L
Journal
Microbiology spectrum
Year
2024
Keywords:
BMI, NAFLD, NASH, children, gut microbiota, metabolism
In China, 45% of adolescents with obesity develop fatty liver disease, a condition that increases the long-term risk of developing cirrhosis and liver cancer. Although the factors triggering nonalcoholic fatty liver disease (NAFLD) vary in children, the composition of intestinal microflora has been found to play an increasingly important role. However, evidence is limited on the prevalence of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) in Chinese children. Therefore, this study aimed to evaluate the fecal microbiome of Chinese children with NAFLD and further analyze the potential of flora in regulating NAFLD-related symptoms and metabolic functions. Specifically, the study applied a 16S rRNA and metagenomic sequencing to the fecal samples of pediatric patients with NAFLD, NASH, and NAFL, as well as healthy controls, to explore the correlation among NAFLD-related indexes, metabolic pathways, and gut flora. The findings showed that some fecal microbiota had a negative correlation with body mass index, and various NAFLD-related bacteria, including Lachnoclostridium, Escherichia-Shigella, and Faecalibacterium prausnitzii, were detected. Consequently, the study concluded that the variation in gut microbiota might be more important in improving NAFLD/NASH compared with single species, providing a microbiota diagnostic profile of NAFLD/NASH.IMPORTANCEThis study aims to characterize the gut microbiota in Chinese children with nonalcoholic fatty liver disease (NAFLD) through 16S rRNA and metagenomic sequencing. The results highlight the association between fecal microbiota and NAFLD in Chinese children, demonstrating distinct characteristics compared to adults and children from other countries. Based on the sequencing data from our cohort's fecal samples, we propose a microbiota model with a high area under the curve for distinguishing between NAFLD and healthy individuals. Furthermore, our follow-up study reveals that changes in the relative abundance of microbial biomarkers in this model are consistent with variations in patients' body mass index. These findings suggest the potential utility of the microbiota model and microbial biomarkers for diagnosing and treating NAFLD in children.
Experiment 1
Needs review
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Non-alcoholic fatty liver disease fatty liver disease, nonalcoholic,fatty liver disease, nonalcoholic, susceptibility to, 1,liver disease, alcoholic, susceptibility to, 1,NAFLD - Nonalcoholic Fatty Liver Disease,NAFLD - nonalcoholic fatty liver disease,NAFLD1,non-alcoholic fatty liver,non-alcoholic fatty liver disease,Nonalcoholic Fatty Liver Disease,nonalcoholic fatty liver disease,Non-alcoholic fatty liver disease
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Healthy controls
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Non-alcoholic fatty liver disease (NAFLD)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Pediatric patients with non-alcoholic fatty liver disease (NAFLD) whose body mass index (BMI) was higher than the 95th percentile and defined through a clinical evaluation and liver ultrasonography
- Group 0 sample size Number of subjects in the control (unexposed) group
- 35
- Group 1 sample size Number of subjects in the case (exposed) group
- 79
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- Antibiotic intake within 2 months or probiotics use within a month before enrollment were excluded.
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V3-V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- unchanged
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Chao1 Abundance-based estimator of species richness
- unchanged
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Needs review
Source: Fig 3
Description: Multiple bacterial species with significantly different abundance found in the intestinal flora of patients with non-alcoholic fatty liver disease (NAFLD) and healthy controls (HCs)
Abundance in Group 1: increased abundance in Non-alcoholic fatty liver disease (NAFLD)
Revision editor(s): Scholastica
Signature 2
Needs review
Source: Fig 3
Description: Multiple bacterial species with significantly different abundance found in the intestinal flora of patients with non-alcoholic fatty liver disease (NAFLD) and healthy controls (HCs)
Abundance in Group 1: decreased abundance in Non-alcoholic fatty liver disease (NAFLD)
Revision editor(s): Scholastica, Ayibatari
Experiment 2
Needs review
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Non-alcoholic steatohepatitis NASH,nash - nonalcoholic Steatohepatitis,non alcoholic steatohepatitis,non-alcoholic steatohepatitis,nonalcoholic Steatohepatitis,nonalcoholic steatohepatitis,Non-alcoholic steatohepatitis
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- NAFL (Non-alcoholic fatty liver) patients
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- NASH (Non-alcoholic steatohepatitis) patients
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- NAFLD patients with the presence of hepatic steatosis with necroinflammation and hepatocellular injury with or without fibrosis
- Group 0 sample size Number of subjects in the control (unexposed) group
- 5
- Group 1 sample size Number of subjects in the case (exposed) group
- 8
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- None
Lab analysis
- Sequencing type
- WMS
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
Statistical Analysis
Alpha Diversity
- Pielou Quantifies how equal the community is numerically
- increased
- Shannon Estimator of species richness and species evenness: more weight on species richness
- increased
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- increased
- Richness Number of species
- increased
Signature 1
Needs review
Source: Fig 4C, Fig 4D
Description: Differential diversity and multiple bacterial species with significantly different abundance found in the intestinal flora of patients with NAFL (Non-alcoholic fatty liver) and NASH (Non-alcoholic steatohepatitis)
Abundance in Group 1: increased abundance in NASH (Non-alcoholic steatohepatitis) patients
| NCBI | Quality Control | Links |
|---|---|---|
| Alistipes | ||
| Bacteroides uniformis | ||
| Eubacterium ventriosum | ||
| Lachnospiraceae bacterium 7_1_58FAA | ||
| unclassified Roseburia |
Revision editor(s): Scholastica
Signature 2
Needs review
Source: Fig 4C, Fig 4D
Description: Differential diversity and multiple bacterial species with significantly different abundance found in the intestinal flora of patients with NAFL (Non-alcoholic fatty liver) and NASH (Non-alcoholic steatohepatitis)
Abundance in Group 1: decreased abundance in NASH (Non-alcoholic steatohepatitis) patients
| NCBI | Quality Control | Links |
|---|---|---|
| unclassified Peptostreptococcaceae |
Revision editor(s): Scholastica
Retrieved from "https://bugsigdb.org/w/index.php?title=Study_980&oldid=123793"
Hidden category:
